

1 **Assessment of serological assays for identifying high titer convalescent plasma**

2

3 Christopher W. Farnsworth^a, James Brett Case^b, Karl Hock^a, Rita E. Chen^{a,b}, Jane A.

4 O'Halloran^b, Rachel Presti^b, Charles W. Goss^c, Adriana M. Rauseo^b, Ali Ellebedy^a, Elitza S.

5 Theel^e, Michael S. Diamond^{a,b,d}, and Jeffrey P. Henderson^{a,d,#}

6

7 ^aDepartment of Pathology & Immunology. Washington University School of Medicine. St.

8 Louis, MO.

9 ^bDepartment of Medicine, Division of Infectious Diseases. Washington University School of

10 Medicine. St. Louis, MO.

11 ^cDepartment of Medicine, Division of Biostatistics. Washington University School of Medicine.

12 St. Louis, MO.

13 ^dDepartment of Molecular Microbiology. Washington University School of Medicine. St. Louis,

14 MO.

15 ^eDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo

16 Clinic, Rochester, MN, USA.

17 **# Address for Correspondence**

18 Jeffrey P Henderson, M.D., Ph.D.

19 660 South Euclid Ave, Box 8051

20 St. Louis, MO 63110

21 hendersonj@wustl.edu

22 **Running Title:** COVID-19 serologic assay comparisons

23 **Key words:** Serology, SARS-CoV-2, COVID-19, Convalescent plasma

24 **Conflicts of interest:** CWF- Research funding: Abbott Diagnostics, Beckman Coulter, Siemens

25 Healthineers. Consulting: Roche Diagnostics. JPH- Consulting: Immunome, Inc. EST –

26 Consulting/Advisory Board: Roche Diagnostics, Accelerate Diagnostics, Serimmune Inc.

27 **Words: 3321**

28

29 **ABSTRACT**

30 The COVID-19 pandemic has been accompanied by the largest mobilization of therapeutic
31 convalescent plasma (CCP) in over a century. Initial identification of high titer units was based
32 on dose-response data using the Ortho VITROS IgG assay. The proliferation of SARS-CoV-2
33 serological assays and non-uniform application has led to uncertainty about their
34 interrelationships. The purpose of this study was to establish correlations and analogous cutoffs
35 between commercially available serological tests (Ortho, Abbott, Roche), a spike ELISA, and a
36 virus neutralization assay using convalescent plasma from a cohort of 79 donors from April
37 2020. Relationships relative to FDA-approved cutoffs under the CCP EUA were identified by
38 linear regression and receiver operator characteristic curves. Relative to the Ortho VITROS
39 assay, the r^2 of the Abbott, Roche, the anti-Spike ELISA and the neutralizing assay were 0.58,
40 0.5, 0.82, and 0.44, respectively. The best correlative index for establishing high-titer units was
41 3.82 S/C for the Abbott, 10.89 COI for the Roche, 1:1,202 for the anti-Spike ELISA, and 1:200
42 by the neutralization assay. The overall agreement using derived cutoffs compared to the CCP
43 EUA Ortho VITROS cutoff of 9.5 was 92.4% for Abbott, 84.8% for Roche, 87.3% for the anti-S
44 ELISA and 78.5% for the neutralization assay. Assays based on antibodies against the
45 nucleoprotein (Roche, Abbott) and neutralizing antibody tests were positively associated with the
46 Ortho assay, although their ability to distinguish FDA high-titer specimens was imperfect. The
47 resulting relationships help reconcile results from the large body of serological data generated
48 during the COVID-19 pandemic.

49

50

51

52 **INTRODUCTION**

53 COVID-19 convalescent plasma (CCP) has been one of the primary therapies deployed in the
54 COVID-19 pandemic. In this current iteration of a classic therapy, serological assays to quantify
55 antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)
56 protein play a critical role in characterizing human immune responses and identifying CCP
57 donors. Commercial SARS-CoV-2 serological assays have accordingly emerged at a rapid pace.
58 Within the first year of the pandemic, more serological assays were available for SARS-CoV-2
59 than for any other infectious disease, with over 65 emergency use authorizations (EUA) granted
60 for serological testing alone (1). The CDC and Infectious Diseases Society of America (IDSA)
61 have both defined relatively narrow and limited clinical applications for SARS-CoV-2
62 serological to include CCP donors identification, infection diagnosis in patients more than 14
63 days from symptom onset, and establishing seroprevalence in populations (2–4). However, the
64 clinical utility of these assays has been questioned (5, 6), in part, due to the challenge of
65 reconciling results from serological assays with clinical outcomes (7–9) and poor agreement
66 between commercial serological assays and virus neutralization assays (10–12).

67
68 Identification of CCP with antibody content sufficient for therapeutic use of CCP has emerged as
69 a key quantitative application for SARS-CoV-2 serological assays (2, 5). Anti-S IgG responses
70 in particular were identified early as key correlates of SARS-CoV-2 immunity. At the
71 pandemic's outset, the absence of an FDA-approved serological assay was a major obstacle to
72 identifying CCP units with sufficient antibody content. A highly sensitive and specific laboratory
73 developed S-based ELISA was quickly developed (13) and used to identify CCP donors with
74 antibodies to SARS-CoV-2 following RT-PCR confirmed infection (14). The initial FDA

75 recommendation was to use a minimum titer of 1:160, with an ideal titer \geq 1:320, as a criterion
76 for CCP donation (14). A subsequent study demonstrated that high-titer CCP, which was defined
77 as a signal of \geq 18.45 on the Ortho-Clinical Diagnostics VITROS IgG assay, was associated with
78 lower risk of mortality than those receiving low-titer units in a large retrospective analysis of
79 patients treated through an FDA expanded access protocol (15). A subsequent analysis of this
80 cohort through the Biomedical Advanced Research and Development Authority (BARDA) found
81 that patients receiving CCP with a neutralizing antibody titer $>$ 1:250 experienced lower
82 mortality than those receiving units with titers $<$ 1:250 (16, 17). Neutralizing antibody assays,
83 however, are highly laborious and require biosafety level 3 facilities if using live SARS-CoV-2,
84 limiting their use primarily to research laboratories. As a result, neutralizing assays were
85 correlated with the Ortho Clinical IgG assay, with a minimum signal of 12.0 distinguishing units
86 with high neutralizing titers (18).

87
88 In February 2021, the FDA reissued a letter of authorization for CCP with several revisions to
89 the previous EUA (19). Importantly, this included a decision to release only high-titer CCP units
90 for patient use. Cutoffs were provided so that multiple serological assays could be used to define
91 high-titer CCP and previously established titers approved by the FDA were modified. The titer to
92 establish high-titer units with the Ortho Clinical assay was lowered from 12.0 to \geq 9.5 S/C, and
93 the original anti-S ELISA threshold was raised from 1:320 to \geq 1:2,880 in an ELISA performed
94 at Mt. Sinai Hospital. The revised EUA also established cutoffs for distinguishing high-titer units
95 using seven other commercial serological assays. For example, the Abbott SARS-CoV-2 IgG
96 assay and the Roche Elecsys anti-SARS-CoV-2 assay were approved for qualifying high-titer
97 units with results \geq 4.5 signal-to-cutoff (S/C) and \geq 109 cutoff index (COI), respectively.

98

99 Little published literature is available to correlate neutralizing antibody titers, commercial
100 serological assays, and anti-S ELISAs. Several studies have assessed the positive percent
101 agreement and negative percent agreement (PPA and NPA) between assays (10, 11, 20).
102 However, the signal from other commercial, serological assays that best correlate to anti-S
103 ELISA titers of 1:320, neutralizing titers of 1:250, and the Ortho Clinical S/C of 12.0, have not
104 been determined. The purpose of our study was to establish correlations and analogous cutoffs
105 between widely used commercial serological assays, anti-S ELISA, and neutralizing assays with
106 authentic SARS-CoV-2. The resulting relationships will help reconcile results from the large
107 body of serological studies and CCP trials results that continue to emerge during the COVID-19
108 pandemic.

109

110 **MATERIALS AND METHODS**

111

112 *Human subjects*

113 This study was approved by the Washington University Institutional Review Board. Serum
114 specimens were drawn on patients with RT-PCR-confirmed SARS-CoV-2 infection at least 14
115 days after infection and prior to donation of convalescent plasma. Patient reported demographic
116 information including age, gender, race, comorbidities, and duration of symptoms were collected
117 by survey on each patient. After collection, specimens were immediately frozen in 100 μ L
118 aliquots and stored at -80°C until further analysis.

119

120 *Assays*

121 Specimens were thawed at room temperature and analyzed within 3 days. Three commercial
122 serological assays and an anti-S ELISA granted EUA at Mt. Sinai Hospital, but used on a
123 research basis for this study, were used to directly measure antibody levels in serum specimens.
124 These assays detected antibodies to SARS-CoV-2 S or nucleocapsid proteins. The anti-S ELISA
125 was performed as previously described (13). In short, plasma specimens were diluted to 1:30 in
126 PBS, then serially diluted to 1:65,610 in a 96-well plate (Corning). Wells were washed,
127 incubated with a secondary anti-human IgG, followed by another wash step. Wells were then
128 incubated with o-Phenylenediamine dihydrochloride (Sigma-Aldrich) followed by a stop
129 solution (3M hydrochloric acid). The optical density was then measured at 490 nm and the cutoff
130 for a positive result was determined as an optical density that was three standard deviations
131 above the mean signal from a negative control specimen run with each plate. This signal was
132 extrapolated from the generated curves to quantify the titer (21).

133
134 An authentic SARS-CoV-2 neutralization assay was used to measure neutralizing antibody titers.
135 Focus reduction neutralization assays were performed as previously described (10). SARS-CoV-
136 2 strain n-CoV/USA_WA1/2020 was obtained from the Centers for Disease Control. Virus was
137 propagated in Vero E6 cells in Dulbecco's Modified Eagle Medium (DMEM, Corning) that was
138 supplemented with 10% FBS, glucose, L-glutamine, and sodium pyruvate. Patient sera were
139 diluted and incubated with 1×10^2 focus forming units (FFU) of SARS-CoV-2 for 1 h at 37°C.
140 The plasma/virus complex was then added to Vero E6 monolayers at 37°C for 1 h. After
141 overlaying with methylcellulose, cells were harvested at 30 h, methylcellulose was removed, and
142 fixed with 4% paraformaldehyde (PFA) for 20 min. Plates were washed and incubated with 1
143 $\mu\text{g/mL}$ anti-S antibody (CR3022) and HRP conjugated goat anti-human IgG. Infected cells were

144 visualized with TrueBlue peroxidase substrate (KPL) and quantified using an ImmunoSpot
145 microanalyzer (Cellular Technologies). A minimum of eight dilutions was performed for each
146 specimen, a standard curve generated, and the 1/log10 plasma dilution (EC50) determined as the
147 dilution at which 50% of the cells were infected.

148
149 All specimens were analyzed on three commercially available serological assays. The Ortho
150 Clinical VITROS SARS-CoV-2 IgG assay was performed on an Ortho Clinical VITROS 5600
151 Immunodiagnostic System and targets antibodies to the S protein. The Abbott SARS-CoV-2 IgG
152 assay was performed on an Abbott Architect i2000 and detects antibodies to the nucleocapsid
153 protein. The Roche Elecsys anti-SARS-CoV-2 assay was performed on a Cobas e601 and
154 identifies antibodies to the nucleocapsid protein. All commercial assays have FDA EUA as
155 qualitative methods and were performed and interpreted according to the manufacturer's
156 instructions. The positive cutoffs for each assay are 1.0 (S/C), 1.4 (S/C), and 1.0 (COI) for the
157 Ortho Clinical, the Abbott, and the Roche assays, respectively. All three assays report a numeric
158 signal to cut-off that is the amount of signal generated by the sample for each assay relative to
159 the signal from a single calibrator.

160

161 *Statistical analysis*

162 Association between assays were compared with least squares regression to calculate intercept,
163 slope and r^2 . Ideal cutoffs from linear regression were established by interpolating relative to
164 each cutoff. Receiver operator curves (ROC) were also plotted to assess the ideal cutoffs using
165 Youden Index to establish cutoff with maximum positive and negative percent agreement. Final

166 cutoffs for distinguishing high- and low-titers units by each assay were established by averaging
167 across all cutoffs.

168

169 **RESULTS**

170

171 *COVID-19 convalescent plasma donors*

172 Serum specimens were obtained from 79 adults at Washington University/Barnes-Jewish
173 Hospital Medical Center in St. Louis, Missouri, U.S.A., with a history of positive SARS-CoV-2
174 RT-PCR testing who expressed interest in donating CCP between 4/6/2020-4/29/2020. The
175 median age was 49 (range 20-69) (**Table 1**). 55.7% of patients were female, 91.1% were white.
176 The most common comorbidity was asthma. Only 2 patients (2.5%) were hospitalized, and the
177 median duration of symptoms was 12 days (range; 1-31). The median time from symptom onset
178 to positive RT-PCR result was 4 days (range; 0-20).

179

180 Anti-S ELISA IgG titers in this cohort spanned four orders of magnitude (1:21 – 1:17,278) with
181 a median titer of 1:2,315 (**Fig 1A**). A broad range of responses also was evident among
182 commercial serological assays. These results are consistent with substantial variability in
183 antibody responses to SARS-CoV-2 proteins among recovered adults. The median signal of the
184 Ortho Clinical assay was 15.4 S/C (95% CI: 12.7-18.0 S/C) (**Fig 1B**), the Abbott assay was 5.2
185 S/C (95% CI: 4.3-6.1 S/C) (**Fig 1C**), and the Roche assay was 23.94 COI (95% CI: 13.8-37.1
186 COI) (**Fig 1D**). As with the anti-S ELISA IgG, live virus neutralization titers spanned a broad
187 range (1:20 – 1:3,622), with a median titer of 1:316 (95% CI: 1:251-1:398) (**Fig 1E**). These

188 results are consistent with substantial variability in neutralizing antibody responses to SARS-
189 CoV-2 proteins among recovered adults (12).

190

191 *Serological characteristics of donors*

192 Linear relationships between each commercial assay were defined relative to the anti-S ELISA
193 IgG titer, Ortho-Clinical assay, and neutralization titer (**Supplemental Figure 1**). Slopes and
194 intercepts for each commercial assay relative to the anti-S ELISA, Ortho Clinical IgG, and
195 neutralization assay are found in **Table 2**. For the anti-S ELISA IgG titer, the initial FDA titer of
196 1:320 was used to establish high and low titers (**Supplemental Fig. 1A**). Interpolated signal by
197 the Ortho Clinical was 5.13 S/C (4.12-6.04), for the Abbott was 1.39 S/C (0.59 to 1.91) and for
198 the neutralization assay was 1.82 (1.68 to 1.93). Due to poor fit, an interpolated cutoff could not
199 be calculated for the Roche assay. For the Ortho Clinical assay, the cutoff of 12.0 S/C was used
200 to distinguish high- and low-titer units (**Supplemental Fig 1B**). The interpolated signal by the
201 Abbott assay was 3.62 S/C (3.1 to 4.07), for the Roche assay was 7.46 COI (4.78 to 10.73), for
202 the ELISA was 2.96 (2.87 to 3.04), and for the neutralization assay was 2.25 (2.09 to 2.37). Low-
203 and high-titer cutoffs were also calculated at the Ortho Clinical cutoff of 4.62 S/C and 18.45 S/C,
204 respectively. For the neutralization assay, a single cutoff of 1:250 was used to determine low-
205 and high-titer units (**Supplemental Fig 1C**). Relative to the neutralization assay, the interpolated
206 cutoffs for the Ortho Clinical was 12.39 S/C (10.38 to 14.16), for the Abbott was 3.92 S/C (3.14
207 to 4.57), for the Roche assay was 8.45 COI (3.48 to 15.89), and for the anti-S IgG ELISA was
208 3.05 (2.91 to 3.18).

209

210 ROC curves were generated for each serological assay using the Ortho Clinical cutoff of 12 S/C
211 (**Fig 2A**) and the neutralizing cutoff of 1:250 (**Fig 2B**). Relative to the Ortho Clinical assays, all
212 assays had an AUC > 0.8, with the anti-S IgG ELISA having the best correlation (AUC = 0.927).
213 The assay with the greatest correlation with the neutralizing assay was the anti-S IgG ELISA,
214 with an AUC of 0.856 (0.771-0.941). Final cutoffs were established by averaging the ideal
215 cutoffs from linear regression in **Table 2** and the ideal cutoffs from the ROC curves using
216 Youden's Index. Using this approach, the average cutoff for distinguishing high- and low-titer
217 units by the Abbot assay was 3.82 S/C, the Roche assay was 10.89 COI, the anti-S IgG ELISA
218 was 3.08, 1:200 for the neutralization assay and 14.14 S/C for the Ortho-Clinical assay (**Table**
219 **3**). ROC curves were also generated relative to the low and high Ortho-Clinical cutoffs of 4.62
220 S/C and 18.45 S/C, respectively (**Supplemental Fig 2**) and for the low and high neutralizing
221 titers of 1:150 and 1:500, respectively (**Supplemental Fig 3**).

222

223 Specimens were segregated as low- or high-titer using the Ortho Clinical cutoff of 9.5 S/C or 12
224 S/C and scatterplots generated (**Fig. 3A and B**). Using the cutoffs established in **Table 3** (dotted
225 black lines), all four assays (Abbott, Roche, ELISA, and neutralization) demonstrated
226 comparable performance relative to the Ortho Clinical cutoffs of 9.5 S/C and 12 S/C for
227 identifying patients with high and low antibody titers. Decreasing the signal for identifying high-
228 titer plasma on the Ortho Clinical assay led to improved NPA and PPA with the Abbott and
229 Roche assay and an improved NPA with a modest decrease in PPA with the anti-S IgG ELISA
230 and the neutralization titer (**Supplemental Table 1**). The overall agreement using the derived
231 cutoffs with the Ortho Clinical assay cutoff of 9.5 S/C was 92.4% for Abbott, 84.8% for Roche,
232 87.3% for the anti-S ELISA and 78.5% for the neutralization assay. Relative to the FDA Abbott

233 cutoff of 4.5 S/C (dashed gray line) for identifying high-titer units, 5 additional specimens would
234 have been labeled as low-titer by the Abbott but high-titer by the Ortho Clinical assay. Using the
235 FDA cutoff of ≥ 109 COI for the Roche assay, all 79 specimens would have been qualified as
236 low-titer units. Specimens also were segregated as low- or high-titer using the neutralization
237 assay cutoff of 1:250 with similar results (**Fig. 3C**). The tiered Ortho Clinical and neutralizing
238 cutoffs used to identify patients with low medium and high titers are found in **Supplemental**
239 **Figures 4 and 5**, respectively. Patients with high ratios of nucleocapsid to S as measured by the
240 Abbott and Ortho assays were more likely to have low neutralizing antibody titers
241 (**Supplemental Figure 6**).

242

243 **DISCUSSION**

244 Despite accumulating evidence of associations between commercial serological assay values and
245 neutralizing antibody titers with human immunity and CCP efficacy, few published studies
246 permit correlation between the assay formats in use. Here, we tested three widely used
247 commercial serological assays, an EUA anti-S IgG ELISA, and neutralizing antibodies and
248 correlated each assay with the ideal cutoffs for establishing high-titer plasma.

249

250 An important finding from this study is that commercial assays and the anti-S ELISA performed
251 similarly for identifying specimens with high neutralization titers. Our approach using linear
252 regression for the Ortho Clinical assay with the FDA-established cutoff of 12 S/C and the
253 neutralizing titer of 1:250, coupled with ROC curves that established maximal PPA and NPA-
254 identified cutoffs made these assays largely interchangeable for identifying high-titer CCP. The
255 antigenic target of the assay did not change the PPA and NPA, with assays measuring antibodies

256 to the viral S protein performing similarly to those measuring antibodies to the nucleocapsid
257 protein. This finding is similar to other studies from acutely infected patients with severe
258 symptoms and patients with mild symptoms (10, 22).

259
260 It is notable that FDA's reissued CCP authorization letter incorporated multiple EUA serological
261 assays, several of which are included in this report (16). The cutoff for the Abbott assay
262 established here (≥ 3.82 S/C) is similar to the cutoff of ≥ 4.5 S/C established by the FDA. This is
263 despite the lowered Ortho Clinical assay S/C cutoff (from 12 to 9.5) in the reissued CCP EUA
264 (16). Nonetheless, the Abbott assay cutoff of 3.82 S/C had better PPA with the Ortho Clinical
265 cutoffs of 9.5 S/C and 12.0 S/C, without sacrificing NPA. In contrast, the FDA-approved cutoff
266 of 109 COI for the Roche assay would have disqualified all units as low-titer, with a signal
267 approximately 10-fold higher than the ideal cutoff identified in this study. The derived cutoff
268 from this study with the anti-S IgG ELISA (1:1,202) also was lower than that established by the
269 FDA (1:2,880). This resulted in a considerable difference in PPA, with far more convalescent
270 donor units being excluded under the FDA cutoffs for ELISA than for the Ortho Clinical assay.
271 The cutoff identified in our study that best distinguishes neutralizing titers $\geq 1:250$ in the Ortho
272 Clinical assay was 14.14 S/C, higher than the original cutoff of 12.0 S/C from the FDA. An S/C
273 of 9 on the Ortho Clinical assay correlated to a neutralizing titer of $\sim 1:100$. This is notably
274 similar to the neutralizing titer of 1:104 we found to be sufficient to reduce weight loss in mice
275 (23). Nevertheless, the neutralizing assay used in this study cannot be assumed to perform
276 similarly to the assay used in the BARDA study (14, 15) due to non-standardization of SARS-
277 CoV-2 strains, cell lines, and reagents/procedures. These differences underlie the difficulties in

278 harmonizing SARS-CoV-2 serological assay results. These discrepancies should be considered
279 when attempting to use any serological assay as a proxy for measuring neutralizing antibodies.

280
281 Several studies demonstrate survival benefits with early, high-titer CCP administration and in
282 patients with hematological malignancies, implying a continued need to identify CCP or immune
283 globulin donors (15, 24–26). This study attempts to harmonize several commercially available
284 assays that have been extensively studied and published. While numerous studies have addressed
285 the analytical performance of available serological assays, little correlative information is
286 available in the published literature to relate multiple serological assay results. Many blood
287 centers in the US are currently using or switching to Ortho Clinical IgG assay for identification
288 of high-titer units. The data presented here suggest that multiple commercial assays could be
289 used to identify CCP donors with high levels of neutralizing antibodies. This study may also
290 provide useful information for contextualizing previous seroprevalence studies and multiple CCP
291 studies across the literature emerging from this pandemic.

292
293 There are several limitations associated with this study. Among the greatest limitations is the
294 lack of standardization between assays, even among the same manufacturers. This was
295 previously noted with the neutralization assay, though the same is true among commercial
296 assays. Since several of the assays have been designated as qualitative (*i.e.* the Roche, Abbott,
297 and Ortho Clinical assays), there is limited evidence that semi-quantitative results are
298 comparable between different instruments by the same manufacturer above the cutoff. For
299 example, since there is no material to verify linearity at higher concentrations, a result of 15 S/C
300 at one institution using the Ortho Clinical assay may vary from the Ortho Clinical assay at

301 another institution. This may underlie the differences between the established cutoff and FDA
302 cutoff for the Roche assay. In general, this problem will continue to plague the field until
303 quantitative assays are universally adopted and standardized to SARS-CoV-2 antibody reference
304 material, such as that recently released by the World Health Organization (27). This is further
305 complicated by unclear direction as to how to report a qualitative assay result as quantitative
306 under an EUA, which does not permit modification of the manufacturer's Instructions for Use.
307 Another limitation of the current study is that a limited number of assays were evaluated,
308 limiting the generalizability of results. It is also important to note that these specimens were
309 obtained early during the course of the pandemic, and that continued viral evolution (which may
310 lead to extensive antigenic changes in the S protein) means that the quantitative relationships in
311 this manuscript could become outdated. Ongoing studies are required to confirm the
312 relationships established here in patients infected with SARS-CoV-2 variants and using
313 neutralizing assays that utilize SARS-CoV-2 variants. Finally, while these results provide
314 evidence of that the cutoffs identified by the FDA are helpful for identifying high-titer CCP
315 units, there were several specimens by each assay that were not in agreement. These specimens
316 demonstrate the requirement for further study before the cutoffs proposed by the FDA are
317 modified.

318

319 In conclusion, we demonstrate that assays based on nucleoprotein antibodies (Roche, Abbott)
320 and neutralization were positively associated with Ortho assay results (anti-S), though their
321 ability to distinguish FDA high-titer specimens was marginal. Association with a traditional
322 ELISA serologic test was high. All assays were positively associated with neutralization titers,
323 though associations were strongest with S-based assays.

324

325 **ACKNOWLEDGEMENTS**

326 This study utilized samples obtained from the Washington University School of Medicine's
327 COVID-19 biorepository, which is supported by: the Barnes-Jewish Hospital Foundation; the
328 Siteman Cancer Center grant P30 CA091842 from the National Cancer Institute of the National
329 Institutes of Health; and the Washington University Institute of Clinical and Translational
330 Sciences grant UL1TR002345 from the National Center for Advancing Translational Sciences of
331 the National Institutes of Health. J.P.H. acknowledges support from National Institute of
332 Diabetes and Digestive and Kidney Diseases grant RO1DK111930 and the Longer Life
333 Foundation. The content is solely the responsibility of the authors and does not necessarily
334 represent the view of the NIH.

335

336

337 **REFERENCES**

- 338 1. FDA. 2020. In Vitro Diagnostics EUAs. [https://www.fda.gov/medical-devices/coronavirus-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas)
339 [disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas)
340 [euas](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas). Accessed March 2021.
- 341 2. Infectious Diseases Society of America. 2020. IDSA COVID-19 Antibody Testing Primer.
- 342 3. CDC. 2020. Interim Guidelines for COVID-19 Antibody Testing. Centers for Disease
343 Control and Prevention. [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html)
344 [ncov/lab/resources/antibody-tests-guidelines.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html). Accessed March 2021.

- 345 4. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19:
346 Molecular Diagnostic Testing. [https://www.idsociety.org/practice-guideline/covid-19-](https://www.idsociety.org/practice-guideline/covid-19-guideline-diagnostics/)
347 [guideline-diagnostics/](https://www.idsociety.org/practice-guideline/covid-19-guideline-diagnostics/). Accessed January 2021.
- 348 5. Farnsworth CW, Anderson NW. 2020. SARS-CoV-2 Serology: Much Hype, Little Data.
349 Clin Chem 66:875–877.
- 350 6. Theel ES, Slev P, Wheeler S, Couturier MR, Wong SJ, Kadkhoda K. 2020. The Role of
351 Antibody Testing for SARS-CoV-2: Is There One? J Clin Microbiol 58:e00797-20.
- 352 7. Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, Farnsworth
353 CW. 2020. Clinical Performance of Two SARS-CoV-2 Serologic Assays. Clin Chem
354 66:1055–1062.
- 355 8. Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, Farnsworth
356 CW. 2020. Clinical Performance of the Roche SARS-CoV-2 Serologic Assay. Clin Chem
357 66:1107–1109.
- 358 9. Theel ES, Harring J, Hilgart H, Granger D. 2020. Performance Characteristics of Four
359 High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2. J
360 Clin Microbiol 58:e01243-20.
- 361 10. Tang MS, Case JB, Franks CE, Chen RE, Anderson NW, Henderson JP, Diamond MS,
362 Gronowski AM, Farnsworth CW. 2020. Association between SARS-CoV-2 neutralizing
363 antibodies and commercial serological assays. Clin Chem 66:1538-1547.

- 364 11. Bal A, Pozzetto B, Trabaud M-A, Escuret V, Rabilloud M, Langlois-Jacques C, Paul A,
365 Guibert N, D'Aubarede-Frieh C, Massardier-Pilonchery A, Fabien N, Goncalves D,
366 Boibieux A, Morfin-Sherpa F, Pitiot V, Gueyffier F, Lina B, Fassier J-B, Trouillet-Assant
367 S, COVID SER STUDY GROUP. 2021. Evaluation of high-throughput SARS-CoV-2
368 serological assays in a longitudinal cohort of patients with mild COVID-19: clinical
369 sensitivity, specificity and association with virus neutralization test. Clin Chem
370 10.1093/clinchem/hvaa336.
- 371 12. Klein SL, Pekosz A, Park H-S, Ursin RL, Shapiro JR, Benner SE, Littlefield K, Kumar S,
372 Naik HM, Betenbaugh M, Shrestha R, Wu AA, Hughes RM, Burgess I, Caturegli P,
373 Laeyendecker O, Quinn TC, Sullivan DJ, Shoham S, Redd AD, Bloch EM, Casadevall A,
374 Tobian AAR. 2020. Sex, age, and hospitalization drive antibody responses in a COVID-19
375 convalescent plasma donor population. J Clin Invest 130:6141-6150.
- 376 13. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, Jiang
377 K, Arunkumar GA, Jurczynszak D, Polanco J, Bermudez-Gonzalez M, Kleiner G, Aydillo T,
378 Miorin L, Fierer DS, Lugo LA, Kojic EM, Stoeber J, Liu STH, Cunningham-Rundles C,
379 Felgner PL, Moran T, García-Sastre A, Caplivski D, Cheng AC, Kedzierska K, Vapalahti
380 O, Hepojoki JM, Simon V, Krammer F. 2020. A serological assay to detect SARS-CoV-2
381 seroconversion in humans. 7. Nature Medicine 26:1033–1036.
- 382 14. FDA. 2020. Recommendations for Investigational COVID-19 Convalescent Plasma. FDA.
383 FDA. [https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-](https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma)
384 [device-exemption-ide-process-cber/recommendations-investigational-covid-19-](https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma)
385 [convalescent-plasma](https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma). Accessed June 2020.

- 386 15. Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES,
387 Wiggins CC, Bruno KA, Klompas AM, Lesser ER, Kunze KL, Sexton MA, Diaz Soto JC,
388 Baker SE, Shepherd JRA, van Helmond N, Verdun NC, Marks P, van Buskirk CM, Winters
389 JL, Stubbs JR, Rea RF, Hodge DO, Herasevich V, Whelan ER, Clayburn AJ, Larson KF,
390 Ripoll JG, Andersen KJ, Buras MR, Vogt MNP, Dennis JJ, Regimbal RJ, Bauer PR, Blair
391 JE, Paneth NS, Fairweather D, Wright RS, Casadevall A. 2021. Convalescent Plasma
392 Antibody Levels and the Risk of Death from Covid-19. *N Engl J Med* 384:1015-1027.
- 393 16. FDA. 2020. COVID Convalescent Plasma EUA.
394 <https://www.fda.gov/media/141477/download>. Accessed September 2020.
- 395 17. Villa C. COVID-19 Convalescent Plasma EUA Decision.
396 <https://www.fda.gov/media/141480/download> . Accessed January 2021.
- 397 18. FDA. 2020. FDA Issues Emergency Use Authorization for Convalescent Plasma as
398 Potential Promising COVID–19 Treatment, Another Achievement in Administration’s
399 Fight Against Pandemic. [https://www.fda.gov/news-events/press-announcements/fda-
400 issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-
401 treatment](https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment). Accessed December 2020.
- 402 19. FDA. 2021. Revised COVID Convalescent Plasma EUA.
403 <https://www.fda.gov/media/141477/download>. Accessed March 2021.
- 404 20. Suhandynata RT, Hoffman MA, Huang D, Tran JT, Kelner MJ, Reed SL, McLawhon RW,
405 Voss JE, Nemazee D, Fitzgerald RL. 2021. Commercial Serology Assays Predict
406 Neutralization Activity against SARS-CoV-2. *Clin Chem* 67:404–414.

- 407 21. FDA. Mount Sinai Laboratory COVID-19 ELISA IgG Antibody Test EUA Summary.
408 <https://www.fda.gov/media/137032/download>. Accessed March 2021.
- 409 22. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, Liao P, Qiu J-F, Lin Y, Cai
410 X-F, Wang D-Q, Hu Y, Ren J-H, Tang N, Xu Y-Y, Yu L-H, Mo Z, Gong F, Zhang X-L,
411 Tian W-G, Hu L, Zhang X-X, Xiang J-L, Du H-X, Liu H-W, Lang C-H, Luo X-H, Wu S-B,
412 Cui X-P, Zhou Z, Zhu M-M, Wang J, Xue C-J, Li X-F, Wang L, Li Z-J, Wang K, Niu C-C,
413 Yang Q-J, Tang X-J, Zhang Y, Liu X-M, Li J-J, Zhang D-C, Zhang F, Liu P, Yuan J, Li Q,
414 Hu J-L, Chen J, Huang A-L. 2020. Antibody responses to SARS-CoV-2 in patients with
415 COVID-19. *Nat Med* 26:845–848.
- 416 23. Winkler ES, Gilchuk P, Yu J, Bailey AL, Chen RE, Chong Z, Zost SJ, Jang H, Huang Y,
417 Allen JD, Case JB, Sutton RE, Carnahan RH, Darling TL, Boon ACM, Mack M, Head RD,
418 Ross TM, Crowe JE, Diamond MS. 2021. Human neutralizing antibodies against SARS-
419 CoV-2 require intact Fc effector functions for optimal therapeutic protection. *Cell*
420 <https://doi.org/10.1016/j.cell.2021.02.026>.
- 421 24. Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, Wiggins CC,
422 Bruno KA, Klompas AM, Lesser ER, Kunze KL, Sexton MA, Diaz Soto JC, Baker SE,
423 Shepherd JRA, van Helmond N, van Buskirk CM, Winters JL, Stubbs JR, Rea RF, Hodge
424 DO, Herasevich V, Whelan ER, Clayburn AJ, Larson KF, Ripoll JG, Andersen KJ, Buras
425 MR, Vogt MNP, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, Paneth NS, Fairweather D,
426 Wright RS, Carter RE, Casadevall A. 2020. Effect of Convalescent Plasma on Mortality
427 among Hospitalized Patients with COVID-19: Initial Three-Month Experience. *medRxiv*
428 <https://doi.org/10.1101/2020.08.12.20169359>.

429 25. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan
430 M, Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y,
431 Chen W, Peng Y, Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng
432 K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen
433 S, Chen Z, Zhang X, Yang X. 2020. Effectiveness of convalescent plasma therapy in severe
434 COVID-19 patients. *Proc Natl Acad Sci USA* 117:9490–9496.

435 26. Thompson MA, Henderon JP, Shah PK, Rubinsteain SM, Joyner MJ, Choueiri TK, Flora
436 DB, Griffiths EA, Gulati AP, Hwang C, Koshkin VS, Papadopoulos EB, Robilotti EV, Su
437 CT, Wulff-Burchfield EM, Xie Z, Yu PP, Mishra S, Senefeld JW, Shah DP, Warner JL.
438 Convalescent Plasma and Improved Survival in Patients with Hematologic Malignancies
439 and COVID-19 | medRxiv.
440 <https://www.medrxiv.org/content/10.1101/2021.02.05.21250953v1>

441 27. WHO. 2021. First WHO International Standard Anti-SARS-CoV-2 Immunoglobulin
442 (Human).
443 https://www.nibsc.org/products/brm_product_catalogue/detail_page.aspx?catid=20/136.

444

445

446

447

448

449

450

451
452
453
454
455
456
457
458
459
460
461

Table 1. Convalescent plasma donors' characteristics

Variable	Total n=79 (%)
Age (median [range])	49 (20-69)
Sex	
Female	44 (55.7)
Male	35 (44.3)
Race	
White	72 (91.1)
Black	4 (5.1)
Asian	2 (2.5)
Other	1 (1.3)
Comorbidities	
Asthma	15 (19)
Lung disease	0 (0)
Heart disease	2 (2.5)

Hypertension	13 (16.5)
Diabetes mellitus	3 (3.8)
Cancer	6 (7.6)
Autoimmune disease	5 (6.3)
Other	28 (35.4)
Hospitalization	2 (2.5)
Duration of symptoms in days (median [range])	12 (1-31)
Days from symptom onset to positive test (median [range])	4 (0-20)

462

463

464 **Table 2.** Linear fit and interpolated cutoffs for each assay

		Ortho Clinical	Abbott	Roche	anti-S ELISA	Neutralizing
anti-S ELISA Titer	Intercept	-632.5	-359.5	467.9		-2875
	(95% CI)	(-1062 to -203.1)	(-993.0 to 210.2)	(53.7 to 882.2)		(-4281.0 to -1468.0)
	Slope (95% CI)	121.2 (96.05 to 146.4)	337.3 (221.7 to 452.9)	21.0 (11.8 to 30.2)		1625.0 (1070.0 to 2180.0)
	r ²	0.54	0.3	0.21		0.31
	FDA cutoff 1:320 (95% CI)	5.13 (4.12-6.04)	1.39 (0.59 to 1.91)	NA*		1.82 (1.68 to 1.93)
	FDA cutoff 1:2,884	17.75 (16.8 to-18.75)	5.64 (5.23 to 6.07)	52.53 (43.05 to 65.31)		2.69 (2.62 to 2.774)
Ortho-Clinical	Intercept (95% CI)		1.72 (-1.1 to 4.55)	9.64 (7.29 to 11.99)	-24.549 (-28.74 to -20.24)	-14.77 (-22.44 to -7.1)
	Slope (95% CI)		2.83 (2.29 to 3.38)	0.16 (0.1 to 0.21)	12.12 (10.83 to 13.4)	11.91 (8.89 to 14.94)
	r ²		0.58	0.5	0.82	0.44
	FDA cutoff 12 (95% CI)		3.62 (3.1 to 4.07)	7.46 (4.78 to 10.73)	3.01 (2.87 to 3.04)	2.25 (2.09 to 2.37)
	High Cutoff 18.45(95% CI)		5.91 (5.45 to 6.46)	41.02 (2.73 to 84.33)	3.54 (3.46 to 3.64)	2.79 (2.66 to 2.96)
	Low Cutoff 4.62 (95% CI)		1.02 (0.03 to 1.73)	1.06 (0.43 to 1.93)	2.4 (2.28 to 2.51)	1.63 (1.3 to 1.83)
	Neutralizing					

(EC50)	Intercept (95% CI)	1.94 (1.77 to 2.1)	9.64 (7.29 to 11.99)	2.09 (1.9 to 2.28)	0.59 (0.24 to 0.94)	
	Slope (95% CI)	0.04 (0.03 to 0.05)	0.16 (0.1 to 0.21)	0.34 (0.2 to 0.47)	0.59 (0.48 to 0.69)	
	r ²	0.44	0.5	0.24	0.61	
	FDA cutoff 250 (95% CI)	12.39 (10.38 to 14.16)	3.92 (3.14 to 4.57)	8.45 (3.48 to 15.89)	3.09 (2.97 to 3.2)	
	High Cutoff 500 (95% CI)	20.49 (18.56 to 22.94)	6.28 (5.58 to 7.23)	67.04 (33.4 to > assay)	3.61 (3.49 to 3.75)	
	Low Cutoff 125 (95% CI)	12.39 (10.38 to 14.16)	1.58 (0.11 to 2.48)	1.07 (0.01 to 2.78)	2.58 (2.38 to 2.72)	

465

466

467

468

469 **Table 3.** PPA and NPA for each assay at various cutoffs relative to the Ortho Clinical assay and

470 Neutralizing titers

471

		Ortho-Clinical		Neutralizing Titer		
		FDA cutoff 12	Youden Index	FDA cutoff 250	Youden Index	Mean
Abbott						
	Cutoff	3.62	3.78	3.92	3.96	3.82
	PPA (95% C)	92.3 (81.8 to 97.0)	92.3 (81.8 to 97.0)	87.2 (74.8 to 94.0)	87.2 (74.8 to 94.0)	
	NPA (95% CI)	74.1 (55.3 to 86.8)	81.5 (63.3 to 91.8)	68.8 (51.4 to 82.1)	68.8 (51.4 to 82.1)	
Roche						
	Cutoff	7.46	16.78	8.45	10.86	10.89
	PPA (95% C)	90.4 (79.4 to 95.8)	82.7 (70.3 to 90.6)	87.2 (74.8 to 94.0)	81.1 (72.3 to 92.6)	
	NPA (95% CI)	62.96 (44.2 to 78.5)	85.2 (67.5 to 94.1)	59.4 (42.3 to 74.5)	56.3 (39.3 to 71.8)	
ELISA						
	Cutoff	2.96	3.04	3.05	3.25	3.08
	PPA (95% C)	94.23 (84.4 to 98.4)	92.3 (81.8 to 97.0)	85.1 (72.3 to 92.6)	83.0 (69.9 to 91.1)	
	NPA (95% CI)	74.07 (55.3 to 86.8)	85.2 (67.5 to 94.1)	65.6 (48.3 to 79.6)	75.0 (57.9 to 86.8)	

Neut/ Titer						
	Cutoff	2.25	2.34			2.30
	PPA (95% C)	86.5 (74.7 to 93.3)	84.6 (72.5 to 92.0)			
	NPA (95% CI)	55.6 (37.3 to 72.4)	66.7 (47.8 to 81.4)			
Ortho-Clinical						
	Cutoff			12.38	15.9	14.14
	PPA (95% C)			80.9 (67.5 to 89.6)	70.2 (56.0 to 81.4)	
	NPA (95% CI)			59.4 (42.3 to 74.5)	84.4 (66.3 to 93.1)	

472
473

474

475

476

477 **Figure Legends**

478 **Figure 1.** Histogram of each assay for 79 convalescent plasma donors with confirmed SARS-
479 CoV-2 infection. Dashed line is the median.

480

481 **Figure 2.** ROC Curves for serological SARS-CoV-2 assays with **A.** the Ortho-Clinical IgG assay
482 using a cutoff of 12 to distinguish high titers and **B.** neutralizing assay using a cutoff of 250.

483

484 **Figure 3.** Scatter plots of EUA serological SARS-CoV-2 assays using the ideal cutoffs identified
485 by linear regression and ROC curves relative to **A.** Ortho-Clinical cutoff of 9.5, **B.** Ortho Clinical
486 cutoff of 12.0 and **C.** a neutralizing titer cutoff of 1:250. Dotted line represents the mean cutoffs
487 identified in Table 3. Dashed lines represent the FDA approved cutoffs from EUA.




Figure 1




Figure 2




Figure 3